Abstract:Purpose The primary objective of the study is to enhance the accuracy and efficiency of assessing the proliferation index in cancer cells, specifically focusing on the role of Ki-67. The purpose is to address the limitations of traditional visual assessments conducted by pathologists by integrating AI technologies, particularly deep learning. By accurately computing the percentage of Ki-67-labeled cells, the research aims to streamline the diagnostic process, reduce subjectivity and contribute to the advancement of diagnostic precision in pathological anatomy. Design/methodology/approach The research employs a methodological approach that integrates Ki-67, a non-histone nuclear protein, as a vital biomarker for assessing the proliferative status of cancer cells. Given the challenges associated with traditional visual assessments by pathologists, including inter- and intra-observer variability and time-consuming efforts, the study adopts a novel methodology leveraging artificial intelligence (AI) solutions. Deep learning is applied to precisely calculate the percentage of Ki-67-labeled cells. The process involves pathologists delineating the tumor area at x40 magnification, enabling the segmentation of various cell types (positive, negative and tumor-infiltrating lymphocytes). The subsequent percentage calculation enhances efficiency and minimizes subjectivity in the diagnostic process. Findings Despite inherent errors, the research findings indicate that the model surpasses existing benchmarks, showcasing superior accuracy in terms of average error measurement. The comparison with diverse datasets and benchmarking against pathologists' diagnoses contributes empirical evidence to support the effectiveness of the AI-based model in accurately computing the percentage of Ki-67-labeled cells. These findings signify a noteworthy advancement in diagnostic methodologies and reinforce the potential of AI technologies in improving the precision of cancer diagnostics within the realm of pathological anatomy. Originality/value The research contributes to the field by introducing an innovative approach that combines Ki-67 as a biomarker and AI technologies for improved diagnostic precision. The originality lies in the utilization of deep learning to calculate the percentage of labeled cells, mitigating the challenges associated with manual assessments. The validation of the model against diverse datasets and benchmarking against pathologists' diagnoses demonstrates its superior accuracy, highlighting the value of integrating AI in pathological anatomy for enhanced diagnostic outcomes. The study represents a significant stride in original research, offering novel insights and methodologies in the pursuit of more precise cancer diagnostics.

Immunohistochemical double nuclear staining for cell-specific automated quantification of the proliferation index - A promising diagnostic aid for melanocytic lesions

Reliability and Variability of Ki-67 Digital Image Analysis Methods for Clinical Diagnostics in Breast Cancer

Histopathologist-level quantification of Ki-67 immunoexpression in gastroenteropancreatic neuroendocrine tumors using semiautomated method

Digital quantification of PRAME for distinguishing melanoma from nevi compared to manual assessment

Advancing Ki67 hotspot detection in breast cancer: a comparative analysis of automated digital image analysis algorithms

Automated Ki‐67 labeling index assessment in prostate cancer using artificial intelligence and multiplex fluorescence immunohistochemistry

Ki-67 Index Measurement in Breast Cancer Using Digital Image Analysis

A Scoring Method for Immunohistochemical Staining on Ki67

Optimized Ki-67 staining in murine cells: a tool to determine cell proliferation

Determination of Ki-67 indices in neuroendocrine tumours of the gastrointestinal tract: the past, the present, and the future

A deep learning model to predict Ki-67 positivity in oral squamous cell carcinoma

Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma

Automated imaging analysis of Ki-67 immunohistochemistry on whole slide images of cell blocks from pancreatic neuroendocrine neoplasms

Comparison of FDA-Approved vs. Mayo Clinic’s Ki-67 Immunostaining Protocols for Breast Cancer Specimens: A Quantitative Analysis Using Artificial Intelligence (AI) Based Image Analysis Algorithms

Synaptophysin-Ki67 double stain: a novel technique that improves interobserver agreement in the grading of well-differentiated gastrointestinal neuroendocrine tumors

AI-powered precision: breast carcinoma diagnosis through digital proliferation index (Ki-67) assessment in pathological anatomy

Dual PD-L1/SOX10 Immunohistochemistry Combined With Digital Imaging Enhances Stratification Accuracy of Patients With Metastatic Melanoma

Improving the diagnosis of ductal carcinoma in situ with microinvasion without immunohistochemistry: An innovative method with H&E‐stained and multiphoton microscopy images

Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group

Clinical validity and clinical utility of Ki67 in early breast cancer